



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, June 8, 2017
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jennifer Brinton, M.D., Board Chair
Neal Catalano, Pharm.D.
Holly Gurgle, Pharm.D.
Steve Lore, M.D.
Kim Michelson, D.D.S.

Eric Cannon, Pharm.D., FAMCP
Ben Berrett, Pharm.D.
Sharon Weinstein, M.D.
Michael Symond, M.D.

Board Members Excused:

Dr. Aesha Drozdowski
Dr. Kumar Shah
Dr. Katherine Smith
Dr. Keith Tolman

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Susan Siegfried, M.D.
Robyn Seely, Pharm.D., DUR Manager
Bryan Larson, Pharm.D., P&T Manager

Andrea Rico, CPhT
Alyssa Pitts, R.N., P.A.
Merelynn Berrett, R.N., PA
Heather Santacruz, R.N., PA

Other Individuals Present:

Robert Nohavec, U of U
Joanita Lake, U of U
Melissa Walsh, Novartis
Tony Locke, Tris Pharma
Charissa Anne, J & J
Valerie Gonzalez, U of U

Susan Kelly, Spark Therapeutics
Drew Favero, U of U
Scott Clegg, Lilly
Cody Ball, SelectHealth
Laura Britton, Healthy U
Russell Frandsen, Legislative Fiscal Analyst

Meeting conducted by: Board Chair

1. **Welcome & Housekeeping:** Jennifer Brinton opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of Choose an item Minutes:** Kim Michelson made a motion to Approve the minutes from May. Holly Gurgle seconded the motion. Unanimous Approval.
3. **Entresto:**
 - a. **Information:** Robyn Seely presenting information on the Entresto utilization: 20 PA requests which included 6 approved, 0 denied, and 14 who had primary other

coverage with another payer.

- b. **Public Comment:** None
 - c. **Board Discussion:** An automatic PA will be given at the pharmacy point of sale, with no intervention from prescriber or pharmacist, if the following are met: Minimum age requirement 18 years old, Trial on an ACEI or an ARB, NOT taking aliskiren (e.g. Tekturna or Tekturna HCT), NOT pregnant (if applicable) OR Diagnosis of systolic heart failure or reduced left ventricular ejection fraction. If the previous criteria is not met, the medication will reject at point of sale for prior authorization required.
 - d. **Board Action:** Michael Symond motioned to apply the above-mentioned automatic prior authorization. Sharon Weinstein seconded. Unanimous approval.
4. **New Basal Insulins:**
- a. **Information:** Joanita Lake presented a review of New Basal Insulins. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
 - b. **Public Comment:** None
 - c. **Board Discussion:** Robyn stated the quantity limits on insulin pens are not a concern. Jennifer Brinton suggested the new basal insulins might benefit from a provider education blast with positive statements.
 - d. **Board Action:** Motion and unanimous approval for provider education piece on new basal insulins.
5. **Public Meeting Adjourned:** Susan Weinstein motioned to close the meeting. Unanimous Approval.
6. **The next meeting scheduled for Thursday, July 13, 2017** Benzodiazepines.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>